GlycoVaxyn AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Private, Subsidiary
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.glycovaxyn.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Vaccine Against Escherichia Coli Infection
Phase 1
Completed
- Conditions
- E.Coli Infections
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- GlycoVaxyn AG
- Target Recruit Count
- 194
- Registration Number
- NCT02289794
- Locations
- 🇨🇭
Hôpitaux Universitaires de Genève, Geneve, GE, Switzerland
Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella
Phase 1
Completed
- Conditions
- Shigellosis
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- GlycoVaxyn AG
- Target Recruit Count
- 40
- Registration Number
- NCT01069471
- Locations
- 🇨🇭
Institute of Social and Preventive Medicine, Zurich, Switzerland
News
No news found